Nancy C. Andrews
CIK: 0001804999
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Aug 18, 2026CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Exercise(M)Direct573 shares at avg. $164.30$94K - Aug 18, 2026CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Sale(S)Direct573 shares at avg. $285.24$163K - Jun 8, 2026MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
18K shares- - May 12, 2026CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Gift(G)Direct4K shares- - May 12, 2026CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Gift(G)Indirect4K shares- - May 8, 2026CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Award(A)Direct1.4K shares at avg. $177.62$255K - Sep 22, 2025MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
18K shares- - May 21, 2025CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Award(A)Direct946 shares at avg. $134.98$128K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 18, 2026 |  CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Exercise(M) | 573 | $164.30 | $94,144 | Direct |
| Aug 18, 2026 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Sale(S) | 573 | $285.24 | $163,443 | Direct |
| Jun 8, 2026 |  MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 18,000 | - | - | Direct |
| May 12, 2026 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Gift(G) | 3,964 | - | $0 | Direct |
| May 12, 2026 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Gift(G) | 3,964 | - | $0 | Indirect |
| May 8, 2026 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Award(A) | 1,438 | $177.62 | $255,418 | Direct |
| Sep 22, 2025 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 18,000 | - | - | Direct |
| May 21, 2025 | CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Award(A) | 946 | $134.98 | $127,691 | Direct |
1-8 of 8 transactions
About Andrews Nancy C
Andrews Nancy C (SEC CIK 0001804999) files insider reports with the SEC as Director of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) and Director of Maze Therapeutics, Inc. (MAZE).
Signal8 holds 7 ownership filings by Andrews Nancy C (1 Form 3, 6 Form 4), filed between Jan 30, 2025 and Aug 20, 2026. Those filings report 8 transactions, from May 21, 2025 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Andrews Nancy C's filings is in WILMINGTON, MA.
Recent filings by Andrews Nancy C
- Aug 18, 2026: Option exercise of CRL shares (Form 4, code M).
- Aug 18, 2026: Open-market sale of CRL shares (Form 4, code S).
- Jun 8, 2026: Grant or award of MAZE derivative securities (Form 4, code A).
- May 12, 2026: Gifts of CRL shares (2 lines, Form 4, code G).
- May 8, 2026: Grant or award of CRL shares (Form 4, code A).
Other insiders filing for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
- FOSTER JAMES C, Director
- Parisotto Shannon M, CEVP, Disc & Safety Assessment
- Coleman Glenn, EVP & Chief Financial Officer
- Girshick Birgit, Chief Executive Officer
- LaPlume Joseph W, EVP, Corp Strategy & Develop
- Knell Michael Gunnar, SVP, Finance and CAO